

Attendees: Adriansjah Azhari (AA), Anand Kumar (AK), Suresh Jadhav (SJ), Harshet Jain (HJ), Raches Ella (RE), Marcus Freire (MF), Yuri Vasilev (YV), Ladda Suwitruengrit (LS), Valeria Brizzio (VB), Linsen Du (LD), Lily (L), Sonia Pagliusi (SP), Sonia Villasenor (SV), and Apoorv Kumar (AP).

DCVMN COVID-19 Committee TC 29 June 2020: started at 12.08 pm and finished at 13.02 pm CET

The Chair, AA, welcomed all members.

The committee reviewed the ToR, with the goal to assess and share technologies important for COVID vaccine development, through surveys and reports. Europe was added as part of the continents where DCVMN members are from (e.g. Russia) and YV proposed to add objective number 5 onto sharing reports and develop surveys. The ToRs were approved and will be circulated within the members of the committee.

SP provided an overview of the World Economic Forum (WEF) Vaccine summit, held on June 26th, 2020, which convened economic leaders to foster development and proposed to create manufacturers alliance for COVID vaccines and called it MANAGE-COV (Manufacturers Alliance for Global Equitable Access to Coronavirus Vaccines). Sai Prasad participated as DCVMN President together with manufacturers, World Bank, GAVI, CEPI, UK, India and Japan representative. A concern raised by manufacturers is that despite the huge efforts in fundraising, developing country manufacturers did not access any funding yet. The International Financing Corporation (World Bank) presented their financial support tools to manufacturers based on loans, not grants, nor advanced commitments. The slides of the presentation presented by SP are attached. ACTION: SP to ask IFC to provide a webinar to members (already done on 29th June 2020).

ACT accelerator, investment case was finalized last week, cf. [https://www.who.int/docs/default-source/coronaviruse/act-consolidated-investment-case-at-26-june-2020-\(vf\).pdf?sfvrsn=2f9386e4_2](https://www.who.int/docs/default-source/coronaviruse/act-consolidated-investment-case-at-26-june-2020-(vf).pdf?sfvrsn=2f9386e4_2) with total investments needed for COVID, vaccines, therapeutics and diagnostics, and the number of doses needed from the next 18 to 24 months. Vaccines are the most cost-effective tool to finish the pandemic. Allocated Funding for R&D, manufacturing, procurement and delivery, considering funds for the future and funds needed immediately. Immediate needs (18 months) are around 11 Bn USD.

Saturday 27th June, there was another pledge event led by European Commission and funding increased by 6.9 Bn USD in cash, loans, but it is not clear how manufacturers will have access to it.

CEPI sent a query to DCVMN to nominate at least 2 representatives to support the COVAX Technical Working Group, which was discussed with EC and suggested to have Adriansjah Azhari to represent DCVMN as Chair of committee and he will report back to the COVID committee; he has expertise in vaccine manufacturing. Weining Meng, from Sinovac, and Ricardo Palacios from Butantan, expert on clinical trials were also nominated, due to the fact that their vaccine is in advanced development stages. The Committee agreed to these nominations.

EDQM has provided open access to the COVID information Package for non-members as well. The package was circulated to DCVMN members on 29th June 2020.

YV suggested that for future presentations we could make short-digest of information. YV agreed to prepare a short digest for next session.

The participants then discussed the creation of subcommittees/subgroups and assigned Champions for each one:

- Clinical trials - Raches Ella.
- Partnerships - Yuri V.
- QC (EDQM) and manufacturing (will be proposed next meeting).

For next TC we could address the presentation on clinical development of COVID vaccines.

Next meeting will be 9th July at 12:00.

AA closed the meeting at 13:02

Nyon 29 June 2020

Notes taken by Sonia V., Apoorv and edited by Sonia P.

DRAFT